anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Obesity, diagnosed in 41.1% of African American (AA) men, is a risk factor for prostate cancer (PCa) recurrence, progression, and increased mortality. Obesity is associated with aggressive PCa only in AA men and not White American (WA) men. The overall health of AA PCa patients is also more likely to be adversely affected by comorbid type 2 diabetes (T2D), often an outcome of obesity and a cause of reduced odds of PCa survival. This evidence suggests that preventing and controlling comorbid obesity and T2D in AA men diagnosed with PCa should be a research funding priority.
AIM: The aim of this study is to determine if federally funded PCa clinical trials controlled T2D and obesity.
METHODS: Completed interventional PCa clinical trials conducted in the USA, funded by the NIH or other federal agency, which included males aged 18-64 years, and reported study protocols were included in the study. We examined the intervention modalities used in the trials to determine if any attempted to control obesity and T2D.
RESULTS: Fifty-eight trials met the study inclusion criteria. Of these 11 were excluded from the analysis as they did not report AA men. A total of 5802 men participated in the remaining 47 trials. Of these, 917 (15.8%) were AA and 4885 (84.2%) were WA men. Forty (85.1%) trials used pharmaceutical medication therapies or other clinical procedures. None of the medications or clinical procedures used were indicated for treatment of obesity and T2D. 5 (10.6%) trials addressed treatment preferences, survivorship, coping, function, and incontinence among PCa patients. Only 2 (4.25%) trials examined weight loss and diet.
CONCLUSIONS: None of the completed federally funded PCa clinical trials that included AA men used methods to control T2D. Only an insignificant number (4.25%) attempted to control obesity. This gap in therapeutic optimization to control these comorbid conditions indicates a critical area in need of federal funding priority.
BACKGROUND: congenital diaphragmatic hernia (CDH) is a birth defect occurring in isolated or syndromic (chromosomal or monogenic) conditions. The diaphragmatic defect can be the most common one: left-sided posterolateral, named Bochdalek hernia; or it can be an anterior-retrosternal defect, named Morgagni hernia. Marfan syndrome (MFS) is a rare autosomal dominant inherited condition that affects connective tissue, caused by mutations in fibrillin-1 gene on chromosome 15. To date various types of diaphragmatic defects (about 30 types) have been reported in association with MFS, but they are heterogeneous, including CDH and paraesophageal hernia.
CASE PRESENTATION: We describe the case of a child incidentally diagnosed with Morgagni hernia through a chest X-ray performed due to recurrent respiratory tract infections. Since the diagnosis of CDH, the patient underwent a clinical multidisciplinary follow-up leading to the diagnosis of MFS in accordance with revised Ghent Criteria: the child had typical clinical features and a novel heterozygous de novo single-base deletion in exon 26 of the FBN1 gene, identified by Whole-Exome Sequencing. MFS diagnosis permitted to look for cardiovascular complications and treat them, though asymptomatic, in order to prevent major cardiovascular life-threatening events.
CONCLUSION: Our case shows the importance of a long-term and multidisciplinary follow-up in all children with diagnosis of CDH.
(1) Background: Emerging adulthood, from the age of 18 to 29 years, is a crucial phase for individuals with Type 1 Diabetes Mellitus, as it affects their Health-Related Quality of Life. (2) Methods: This cross-sectional study analyzes the influence of the Mediterranean diet, Diabetes duration, Hemoglobin A1c, and sleep disorders on Health-Relate Quality of Life in Type 1 Diabetes Mellitus. In this study, conducted in Andalusia, Spain, 362 emerging adults with Type 1 Diabetes Mellitus completed the Oviedo Sleep Questionnaire, the Adaptation of Mediterranean Diet Adherence Screener, and the Vida con Diabetes Tipo 1 (ViDa1) Health-Related Quality of Life questionnaire between October 2021 and July 2022. Pearson correlation coefficients and a multiple regression analysis were conducted for each Health-Related Quality of Life in Type 1 Diabetes Mellitus dimension (Interference with Life, Well-being, Self-care, and Concern about the Condition) for overall sample and separately for males and females. (3) Results: Different and significant correlations are found among factors such as Age, Body Mass Index, Currently being a student, Hemoglobin A1c, Sleep satisfaction, Insomnia, Hypersomnolence, and Adherence to Mediterranean diet. Notably, Insomnia is a main predictor for Interference with Life, Well-being, and Concern about the Condition, especially for females. (4) Conclusions: Insomnia is the main predictor of Health-Related Quality of Life in Type 1 Diabetes Mellitus among Andalusian emerging adults with this condition. Consequently, a regular assessment of sleep and Health-Related Quality of Life from a gender perspective in this age group is crucial.
RIPC will consist of setting a tourniquet to donor thigh and inflating it to 300mmHg four times 5 minutes with 5 minutes deflating in between each. RIPC-intervention will be performed twice: First after brain death and second time before procurement procedure.
Either 2 type 2 or type 2 low characteristics. Participants included in this group must report prior biological treatment and having stopped treatment with at least 2 prior asthma biologics. They could be on or off biologic therapy at enrollment and have any level of asthma control by asthma control test and GINA at the time of enrollment.
Vascular endothelial growth factor VEGF is related to the abnormal angiogenesis of meningioma and can also activate other growth factor pathways. Meningiomas are vascular tumors. Studies have shown that the expression of VEGF in atypical meningiomas is twice that of benign meningiomas, and VEGF in anaplastic meningiomas is 10 times that of benign meningiomas. Therefore, anti-angiogenesis therapy may be more effective for higher grade meningiomas. Previous clinical studies have confirmed that anti-angiogenic drugs such as bevacizumab, sunitinib and PTK 787 can slow down tumor growth and prolong progression-free survival for recurrent atypical/malignant meningioma. In summary, apatinib mesylate may be an effective treatment for recurrent atypical/malignant meningioma. This prospective clinical study is now planned to verify the effectiveness and safety of apatinib mesylate in the treatment of relapsed atypical/malignant meningioma.
Participants will receive only Normal Saline for PICC line maintenance. All lumens of PICC line will be flushed every 24 hours with 10cc Normal Saline. PICC line will be flushed with 10cc Normal Saline after administration of medication, blood products, or blood draws.
PURPOSE: To obtain a paste tooth abrasion composition capable of manifesting an anti-plaque and an anti-gingivitis effects by blending a silica abrading agent having a good adaptability to a cationic treating agent with a nonionic thickening agent, surfactant and moisture preserving agent, and by containing an organic cationic treating agent and water. CONSTITUTION: This paste tooth abrasion composition consists of (a) 10-35wt.% silica abrading agent having a good adaptability with a cationic treating agent, (b) 0.25 2.0wt.% nonionic thickening agent, (c) a nonionic surfactant (e.g.; ethyleneoxide), (d) a nonionic moisture maintaining agent (e.g.; sorbitol), (e) 0.1-5.0wt.% organic cationic treating agent (e.g.; a substituted guanidine) and water. The composition exhibits an anti-plaque/an anti-gingivitis effects. The maximum effectiveness of the active ingredients is manifested by this composition ratio. It is preferable to add zinc ion further to this composition.
Regulatory T cell subpopulation (Treg) are isolated for a human host by selection for cells expressing CD4 and CD25. The Treg cells are further characterized by expression of CTLA-4, CCR6, and CD30. In addition, the Treg cells are CD62L hi , CD45RB lo , CD45RO hi , CD45RA − . The Treg cells of the invention reflect the immunologic status of the donor, in terms of the number, location and T cell antigen receptor specificity of the Treg cells. This information is used in diagnostic assays relating to immunologic disorders, e.g. cancer related immunosuppression; autoimmune disorders; atopic states, etc. The isolated Treg cells are useful in transplantation, for experimental evaluation, and as a source of subset and cell specific products, including mRNA species useful in identifying genes specifically expressed in these cells, and as targets for the discovery of factors or molecules that can affect them. Culture assays and systems of interest include the interactions of Treg cells with immature and mature dendritic cells, interactions with T cell subsets, responsiveness to antigen specific and non-specific stimulus, and the like.
PURPOSE: The purpose of this study was to evaluate and determine clinical outcomes and survival rates of straight and extended length subcrestal angulated (ELSA) implants (20-24 mm lengths) placed for immediate (up to 72 h post-operative) or delayed rehabilitation (4 months post-operative) of severely atrophic maxillae. Prosthetic treatment consisted of interim and definitive implant-supported fixed implant-supported prostheses with up to 3 years of function.
MATERIALS AND METHODS: A retrospective analysis was conducted of 38 patients (five dropped out; final total was 33), treated between 2017 and 2019 in a private practice. Extended length subcrestal angulated (ELSA) implants and conventional endosseous straight implants (Southern Implants, Irene, South Africa) with (fixed) full arch prostheses were used to restore patients with edentulous maxillae immediately (within 72 hs) or delayed (4 months).  ELSA implants have subcrestal angulations of 24° and 36° of the restorative platforms, external hexagon crestal anti-rotation abutment connections, and lengths between 18 and 26 mm. Implant loading was determined by implant insertion torque values (as determined on the surgical units); 120 Ncm was the threshold level for immediate loading. Clinical and radiographic examinations were done that recorded the clinical outcomes of implants and prostheses. SPSS was used to process the data.
RESULTS: Thirty-three patients and 187 implants were included with follow-up periods of at least 12 months (range 12-36 months). The mean age of the study population was 62.6 ± 8.4 years old (at the time of implant placement). Thirty-three patients (86.8%) were followed for 12 months; 13 patients (39.4%) were followed for 24-35 months; 9 patients (27.3%) were followed for 36 months. In total, 13 implants in six patients failed secondary to sinus infections. Mean bone levels (MBLs) were respectively: 0.88 ± 2.12 mm at loading, -1.53 ± 2.03 mm at 12 months, -2.26 ± 1.45 mm at 24 months, and -2.54 ± 1.46 mm at 36 months. The ELSA implants showed significantly lower (p = 0.014) MBL at 36 months than did the conventional implants. One hundred thirty-seven implants were placed and loaded within 72 h; 50 implants were placed and loaded 4 months post placement. The combined implant survival rates were 93.0% at 12 months, 91.1% at 24 months, and 100% at 36 months. The ELSA implants showed significantly lower (p = 0.014) MBLs at 36 months when compared to the conventional implants.
CONCLUSIONS: The results of this retrospective clinical chart review indicated that the use of ELSA implants placed into anterior maxillae and nasal crests with accentuated distal tilts (>30°) and simultaneous sinus augmentation provided favorable outcomes for prosthetic rehabilitation in patients with severe atrophic maxillae. ELSA implants placed with simultaneous sinus augmentation are an alternative option to zygomatic implants (ZI) when immediate loading is prescribed. Sinus infections were thought to be the proximate causes of all implant failures. Further long-term clinical studies are warranted with larger patient populations.
<P>PROBLEM TO BE SOLVED: To provide a new therapeutic agent for dealing with a human disease.  <P>SOLUTION: A compound useful as a protein kinase inhibitor is disclosed. A composition including such compound and a method of the use are disclosed. In detail, a compound as an inhibitor of Aurora-2 protein kinase is disclosed. In more detail, a compound of formula IIIa, or a pharmaceutically acceptable derivative or prodrug thereof, and a method treating a disease relevant to a protein kinase, especially a disease relevant to Aurora-2 (for example, cancer) are disclosed.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Associations between gut microbiota and ankylosing spondylitis have been discovered in previous studies, but whether these associations reflect a causal relationship remains inconclusive. Aiming to reveal the bidirectional causal associations between gut microbiota and ankylosing spondylitis, we utilized publicly available genome wide association study summary data for 211 gut microbiota (GM) taxa and ankylosing spondylitis (AS) to conduct two sample mendelian randomization analyses. Mediation analysis was performed to explore mediating inflammatory cytokines. We found that genetically predicted higher abundance of Lactobacillaceae family, Rikenellaceae family and Howardella genus had suggestive associations with decreased risk of ankylosing spondylitis while genetic proxied higher abundance of Actinobacteria class and Ruminococcaceae_NK4A214_group genus was associated with increased risk of ankylosing spondylitis. IL23 and IFN-γ were potential mediating cytokines for GM dysbiosis, especially for Actinobacteria class, leading to AS. Our study provided a new exploration direction for the treatment of AS. Lactobacillaceae family, Rikenellaceae family, Howardella genus, Actinobacteria class and Ruminococcaceae_NK4A214_group genus are expected to become new therapeutic targets and monitoring indicators for AS.
The invention discloses pharmaceutical compositions containing polydatin or its pharmaceutically acceptable salts with the effect of improving microcirculation, and their application in preparing drugs which can improve microcirculation. The compositions are non-gastrointestinal injectable preparations, the preparations can be aqueous solutions which have pH 7.0-10.0, comprising 5-50 % propanediol. The dosage forms of the compositions may be lyophilizing power injection, oral form, suppository of procto-administration and other forms of mero-administration comprising unguent, ointment, past film coating and the like. The compositions may be use to treat and/or prevent diseases related to microcirculation block. The unit form may contain 1-1000mg polydatin or its derivatives. This invention solve the problem of using polydatin to improve microcirculation, the compositions of the invention can be used in treating choc, angiocardiopathy and cerebrovascular diseases, sense organic diseases, neopathy of diabetes, angiemphraxis engeitis, external pile relate to blood circulation block, derma hurt or ambustion.
This invention provides an isolated polypeptide comprising an amino acid sequence of a bacterial zinc metalloprotease in which the amino acid sequence is set forth in SEQ ID NO:2, including fragments, mutants, variants, analogs, or derivatives, thereof. Such zinc metalloprotease is capable of regulating expression of choline binding proteins and/or other proteins on a bacterial cell surface. This invention further provides an isolated immunogenic polypeptide comprising an amino acid sequence of a zinc metalloprotease. This invention provides an isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of a zinc metalloprotease. This invention provides pharmaceutical compositions, vaccines, and diagnostic and therapeutic methods of use of the isolated polypeptides and nucleic acids and antibodies of the present invention. Assays for compounds which alter or inactivate the polypeptides of the present invention for use in therapy are also provided.
Patients receive OCA PO QD for 6 months in the absence of unacceptable toxicity. Patients also undergo GI endoscopy with biopsy and collection of blood samples at screening and on study.
The early-life gut microbiota (GM) is increasingly recognized for its contributions to human health and disease over time. Microbiota composition, influenced by factors like race, geography, lifestyle, and individual differences, is subject to change. The GM serves dual roles, defending against pathogens and shaping the host immune system. Disruptions in microbial composition can lead to immune dysregulation, impacting defense mechanisms. Additionally, GM aids digestion, releasing nutrients and influencing physiological systems like the liver, brain, and endocrine system through microbial metabolites. Dysbiosis disrupts intestinal homeostasis, contributing to age-related diseases. Recent studies are elucidating the bacterial species that characterize a healthy microbiota, defining what constitutes a 'healthy' colonic microbiota. The present review article focuses on the importance of microbiome composition for the development of homeostasis and the roles of GM during aging and the age-related diseases caused by the alteration in gut microbial communities. This article might also help the readers to find treatments targeting GM for the prevention of various diseases linked to it effectively.
The invention discloses an invisible mask suitable for multiple occasions and a preparation method thereof. The invisible mask comprises a substrate layer, a nanofiber film layer and a protective layer. The nanofiber film layer is formed on the non-woven fabric substrate layer by adopting an electrostatic spinning method, and the electrostatic spinning solution for preparing the nanofiber film layer comprises the following components: glycerol, herba Centellae extract, adenosine, nicotinamide, oleum Cocois, essence, 1.2-hexanediol, butanediol, polyvinyl alcohol, cellulose gum, sodium hyaluronate, and hydrolyzed collagen. The substrate layer and the protective layer are preferably spun-bonded polypropylene nonwoven fabrics. Also discloses a preparation method of the invisible mask. The invisible mask comprises: the use is convenient; the nutrient liquid can not drip in the use process; is suitable for multiple occasions and the like.
PROBLEM TO BE SOLVED: To obtain an oral composition excellent in low temperature stability, oral dispersion and feeling in use, and useful as a mouth-washing agent, a dentifrice gent, etc., by compounding a native gellan gum. SOLUTION: This composition is composed of a native gellan gum, i.e., a microorganism produced polysaccharide. A low viscosity liquid oral composition such as a mouth-washing agent, a high viscosity liquid, a pasty or a powdery oral composition such as a dentifrice composition can be produced by compounding the native gellan gum at 0.005-10wt.% of the total composition. The mouth-washing agent preferably has a viscosity of 1-500Pas at 25 deg.C and the compounding ratio of 0.05-0.6wt.% of the native gellan gum, and the dentifrice composition preferably has the compounding ratio of the native gellan gum of 0.05-3wt.%. Thus obtained mouth-washing composition can hold homogeneous stability in low-temperature storage, and has no stickiness and foreign taste.  The obtained dentifrice composition is good in oral dispersion, little in stickiness, excellent in rinse after teeth brushing and god in shape-retainability on a toothbrush.
Severe hepatic injury including cases of hepatic failure, some of which have been due to autoimmune hepatitis, has been rarely reported in patients taking BETASERON. In some cases, these events have occurred in the presence of other drugs or comorbid medical conditions that have been associated with hepatic injury. Consider the potential risk of BETASERON used in combination with known hepatotoxic drugs or other products (eg, alcohol) prior to BETASERON administration, or when adding new agents to the regimen of patients already on BETASERON. Monitor patients for signs and symptoms of hepatic injury. Consider discontinuing BETASERON if serum transaminase levels significantly increase, or if they are associated with clinical symptoms such as jaundice.

Asymptomatic elevation of serum transaminases is common in patients treated with BETASERON. In controlled clinical trials, elevations of SGPT to greater than five times baseline value were reported in 12% of patients receiving BETASERON (compared to 4% on placebo), and increases of SGOT to greater than five times baseline value were reported in 4% of patients receiving BETASERON (compared to 1% on placebo), leading to dose-reduction or discontinuation of treatment in some patients [see Adverse Reactions (6.1)]. Monitor liver function tests [see Warnings and Precautions (5.12)].
We have performed a promising initial trial of periosteal stimulation (PST, that is, electrical stimulation of 4 acupuncture needles around the knee that touch periosteum) as an analgesic for older veterans with advanced knee osteoarthritis (OA) and daily pain. The primary aim of the proposed trial is to optimize and sustain the efficacy of PST for reducing pain in veterans with advanced knee OA and unrelieved pain by combining it with booster PST. Our secondary aims are to 1) improve physical performance in these individuals, and 2) ascertain the physical and psychological predictors of response to PST. In a randomized controlled clinical trial, 180 veterans (age 50 and older) with persistent knee pain who have x-ray evidence of advanced OA will be assigned to one of three intervention groups: 1) control PST once a week for 10 weeks (i.e., needle placement with brief stimulation of non-periosteal needles), 2) PST once a week for 10 weeks followed by tapering PST boosters over 6 months, or 3) PST once a week for 10 weeks followed by tapering control-PST boosters over 6 months. Prior to initiating the intervention, immediately after the last session, and 6 months later, the following parameters will be assessed: 1) pain severity (WOMAC), 3) physical performance (gait velocity, stair climb, repetitive chair rise, timed up and go), and 4) psychological function (mood, coping, self-efficacy). Monthly telephone calls will assess pain, interim illness and physical activity.
FIELD: veterinary science, biotechnology, vaccines. SUBSTANCE: the parent virus for preparing strain "O" is isolated from larynx and trachea of chicken with symptoms of lethal form of sickness in Kazakhstan in 1992. The industrial strain "O" is obtained by multiple successive passages in 9-11 daily old embryos of SPF-chickens. The strain is deposited in Collection of microorganisms VGNKI 05. 06. 2000 at registration name "O = 112-DEP". The strain shows high biological, immunogenic activity both in native form and after inactivation. The strain is cultured in 9-11 daily old embryos of SPF- chickens and in 3-6 days of culturing the infectivity titer is 6.2 lg ЭИД 50 /cm 3 , not less. The strain shows high biological, antigenic and immunogenic activity both in native form and after inactivation and useful for preparing highly specific and sensitive diagnostics and highly immunogenic, harmless and areactogenic vaccine preparations for ocular and oral methods of immunization. EFFECT: valuable properties of strain and preparations. 6 tbl